
SOLAR-1 Trial Reports Overall Survival Benefits in Breast Cancer Patients with Limited Options of Treatment
Results support the use of alpelisib plus fulvestrant for patients with HR-positive, HER2-negative advanced breast cancer and PI3KCA mutations

How is COVID-19 Affecting the Wellbeing of Oncology Professionals?
Dr Susana Banerjee summarises results from two surveys investigating the psychological impact of the pandemic on medical oncologists

Intensive Follow-up Increases Frequency of Curative Intent Secondary Surgery in Colorectal Cancer
Results from the PRODIGE 13 trial, presented at ESMO Virtual Congress 2020, show that optimisation of diagnostic procedures in terms of overall survival benefits remains to be determined

Neoadjuvant Immunotherapy Does Not Find Its Place Yet in Resectable NSCLC
Although disappointing, results from IONESCO and PRINCEPS trials are preliminary

Is Precision Medicine Fulfilling its Promise?
The delivery of precision medicine is still restricted by clinicians’ capability to interpret the genomic alterations and match them with the most appropriate medicines

Dozens of COVID19-Related Articles Retracted: How to Assess the Quality of Research in the COVID-19 Era
Dr Alessandra Curioni-Fontecedro shares her perspectives on the pitfalls of peer reviewing and its impact on the scientific community and the society

Developing National Cancer Control Programmes to Strengthen Health Service Quality Planning
Dr Dario Trapani comments on a study revealing cancer burden projections for 2020 among European Union Member States that provides quality data to formulate informed health policies.

Bringing Innovation to Cancer Patients
Held virtually for the first time this year, ESMO’s annual congress is connecting the oncology community to improve cancer care in the COVID-19 era

Are we reaching a turning point in metastatic prostate cancer?
PROfound study shows benefit in radiological progression-free survival with olaparib in men with BRCA1, BRCA2 or ATM mutations in metastatic castration-resistant prostate cancer